179 related articles for article (PubMed ID: 26725876)
1. Soluble neprilysin does not correlate with outcome in heart failure with preserved ejection fraction.
Goliasch G; Pavo N; Zotter-Tufaro C; Kammerlander A; Duca F; Mascherbauer J; Bonderman D
Eur J Heart Fail; 2016 Jan; 18(1):89-93. PubMed ID: 26725876
[TBL] [Abstract][Full Text] [Related]
2. Biomarkers for characterization of heart failure - Distinction of heart failure with preserved and reduced ejection fraction.
Sinning C; Kempf T; Schwarzl M; Lanfermann S; Ojeda F; Schnabel RB; Zengin E; Wild PS; Lackner KJ; Munzel T; Blankenberg S; Wollert KC; Zeller T; Westermann D
Int J Cardiol; 2017 Jan; 227():272-277. PubMed ID: 27838133
[TBL] [Abstract][Full Text] [Related]
3. Growth differentiation factor 15 in heart failure with preserved vs. reduced ejection fraction.
Chan MM; Santhanakrishnan R; Chong JP; Chen Z; Tai BC; Liew OW; Ng TP; Ling LH; Sim D; Leong KT; Yeo PS; Ong HY; Jaufeerally F; Wong RC; Chai P; Low AF; Richards AM; Lam CS
Eur J Heart Fail; 2016 Jan; 18(1):81-8. PubMed ID: 26497848
[TBL] [Abstract][Full Text] [Related]
4. Multimarker Strategy for Heart Failure Prognostication. Value of Neurohormonal Biomarkers: Neprilysin vs NT-proBNP.
Bayes-Genis A; Barallat J; Galán A; de Antonio M; Domingo M; Zamora E; Gastelurrutia P; Vila J; Peñafiel J; Gálvez-Montón C; Lupón J
Rev Esp Cardiol (Engl Ed); 2015 Dec; 68(12):1075-84. PubMed ID: 26297179
[TBL] [Abstract][Full Text] [Related]
5. Persistent atrial fibrillation in heart failure with preserved ejection fraction: Prognostic relevance and association with clinical, imaging and invasive haemodynamic parameters.
Schönbauer R; Duca F; Kammerlander AA; Aschauer S; Binder C; Zotter-Tufaro C; Koschutnik M; Fiedler L; Roithinger FX; Loewe C; Hengstenberg C; Bonderman D; Mascherbauer J
Eur J Clin Invest; 2020 Feb; 50(2):e13184. PubMed ID: 31732964
[TBL] [Abstract][Full Text] [Related]
6. Bio-profiling and bio-prognostication of chronic heart failure with mid-range ejection fraction.
Moliner P; Lupón J; Barallat J; de Antonio M; Domingo M; Núñez J; Zamora E; Galán A; Santesmases J; Pastor C; Bayes-Genis A
Int J Cardiol; 2018 Apr; 257():188-192. PubMed ID: 29415801
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of NT-proBNP in heart failure with preserved versus reduced EF.
Kang SH; Park JJ; Choi DJ; Yoon CH; Oh IY; Kang SM; Yoo BS; Jeon ES; Kim JJ; Cho MC; Chae SC; Ryu KH; Oh BH;
Heart; 2015 Dec; 101(23):1881-8. PubMed ID: 26319121
[TBL] [Abstract][Full Text] [Related]
8. Adaptive cardiovascular hormones in a spectrum of heart failure phenotypes.
Zabarovskaja S; Hage C; Linde C; Daubert JC; Donal E; Gabrielsen A; Mellbin L; Lund LH
Int J Cardiol; 2015; 189():6-11. PubMed ID: 25885866
[TBL] [Abstract][Full Text] [Related]
9. N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction: findings from the Trial of Intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF).
Maeder MT; Rickenbacher P; Rickli H; Abbühl H; Gutmann M; Erne P; Vuilliomenet A; Peter M; Pfisterer M; Brunner-La Rocca HP;
Eur J Heart Fail; 2013 Oct; 15(10):1148-56. PubMed ID: 23657728
[TBL] [Abstract][Full Text] [Related]
10. Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction.
Santhanakrishnan R; Chong JP; Ng TP; Ling LH; Sim D; Leong KT; Yeo PS; Ong HY; Jaufeerally F; Wong R; Chai P; Low AF; Richards AM; Lam CS
Eur J Heart Fail; 2012 Dec; 14(12):1338-47. PubMed ID: 22869458
[TBL] [Abstract][Full Text] [Related]
11. Interstitial Fibrosis, Functional Status, and Outcomes in Heart Failure With Preserved Ejection Fraction: Insights From a Prospective Cardiac Magnetic Resonance Imaging Study.
Duca F; Kammerlander AA; Zotter-Tufaro C; Aschauer S; Schwaiger ML; Marzluf BA; Bonderman D; Mascherbauer J
Circ Cardiovasc Imaging; 2016 Dec; 9(12):. PubMed ID: 27974408
[TBL] [Abstract][Full Text] [Related]
12. Biomarker Profiles in Heart Failure Patients With Preserved and Reduced Ejection Fraction.
Tromp J; Khan MA; Klip IT; Meyer S; de Boer RA; Jaarsma T; Hillege H; van Veldhuisen DJ; van der Meer P; Voors AA
J Am Heart Assoc; 2017 Mar; 6(4):. PubMed ID: 28360225
[TBL] [Abstract][Full Text] [Related]
13. Soluble neprilysin is predictive of cardiovascular death and heart failure hospitalization in heart failure patients.
Bayés-Genís A; Barallat J; Galán A; de Antonio M; Domingo M; Zamora E; Urrutia A; Lupón J
J Am Coll Cardiol; 2015 Feb; 65(7):657-65. PubMed ID: 25677426
[TBL] [Abstract][Full Text] [Related]
14. The right heart in heart failure with preserved ejection fraction: insights from cardiac magnetic resonance imaging and invasive haemodynamics.
Aschauer S; Kammerlander AA; Zotter-Tufaro C; Ristl R; Pfaffenberger S; Bachmann A; Duca F; Marzluf BA; Bonderman D; Mascherbauer J
Eur J Heart Fail; 2016 Jan; 18(1):71-80. PubMed ID: 26449727
[TBL] [Abstract][Full Text] [Related]
15. Plasma Neprilysin Displays No Relevant Association With Neurohumoral Activation in Chronic HFrEF.
Prausmüller S; Arfsten H; Spinka G; Freitag C; Bartko PE; Goliasch G; Strunk G; Pavo N; Hülsmann M
J Am Heart Assoc; 2020 Jun; 9(11):e015071. PubMed ID: 32427034
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and prognosis of heart failure with preserved ejection fraction and elevated N-terminal pro brain natriuretic peptide: a 10-year analysis from the Copenhagen Hospital Heart Failure Study.
Carlsen CM; Bay M; Kirk V; Gøtze JP; Køber L; Nielsen OW
Eur J Heart Fail; 2012 Mar; 14(3):240-7. PubMed ID: 22315457
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial.
Anand IS; Rector TS; Cleland JG; Kuskowski M; McKelvie RS; Persson H; McMurray JJ; Zile MR; Komajda M; Massie BM; Carson PE
Circ Heart Fail; 2011 Sep; 4(5):569-77. PubMed ID: 21715583
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of tPA/PAI-1 complex in patients with heart failure and preserved ejection fraction.
Winter MP; Kleber ME; Koller L; Sulzgruber P; Scharnagl H; Delgado G; Goliasch G; März W; Niessner A
Thromb Haemost; 2017 Feb; 117(3):471-478. PubMed ID: 27975104
[TBL] [Abstract][Full Text] [Related]
19. How B-Type Natriuretic Peptide (BNP) and Body Weight Changes Vary in Heart Failure With Preserved Ejection Fraction Compared With Reduced Ejection Fraction: Secondary Results of the HABIT (HF Assessment With BNP in the Home) Trial.
Maisel AS; Shah KS; Barnard D; Jaski B; Frivold G; Marais J; Azer M; Miyamoto MI; Lombardo D; Kelsay D; Iqbal N; Taub PR; Kupfer K; Lee E; Clopton P; Zile M; Greenberg B
J Card Fail; 2016 Apr; 22(4):283-93. PubMed ID: 26433086
[TBL] [Abstract][Full Text] [Related]
20. Temporal Relation Between Myocardial Fibrosis and Heart Failure With Preserved Ejection Fraction: Association With Baseline Disease Severity and Subsequent Outcome.
Schelbert EB; Fridman Y; Wong TC; Abu Daya H; Piehler KM; Kadakkal A; Miller CA; Ugander M; Maanja M; Kellman P; Shah DJ; Abebe KZ; Simon MA; Quarta G; Senni M; Butler J; Diez J; Redfield MM; Gheorghiade M
JAMA Cardiol; 2017 Sep; 2(9):995-1006. PubMed ID: 28768311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
